Randomized Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Single-center, randomized clinical trial (RCT) with low intervention level (Telenursing), for the monitoring of patients affected by lung cancer and melanoma who are candidates for first prescription with Targeted Therapies. The study population will consist of patients suffering from lung cancer and melanoma. The objective of the study will be to evaluate the effectiveness of a Telenursing intervention, comparing the mean score of the total SCNs scale (Supportive Care Needs) after one month of treatment in the treatment arm and in the control arm. Enrolled patients will then be randomized into two treatment arms: * Arm 1 (Control Group): current clinical practice * Arm 2 (Experimental group): Telenursing intervention.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• aged between 18 and 75;

• patients suffering from lung cancer and melanoma candidates for the first prescription with Targeted Therapies in exclusive treatment;

• patients able to understand, speak Italian and join the study by signing of paper informed consent;

• possibility of accessing and using the information technologies adopted in trial through a PC/tablet and personal internet connection;

• patients willing to comply with study procedures.

Locations
Other Locations
Italy
Regina Elena National Cancer Institute
RECRUITING
Rome
Contact Information
Primary
Aurora De Leo, Nursing
aurora.deleo@ifo.it
0652662928
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2025-09-01
Participants
Target number of participants: 40
Treatments
No_intervention: Control group: current clinical practice
Experimental: Experimental group: Telenursing intervention
Related Therapeutic Areas
Sponsors
Leads: Regina Elena Cancer Institute

This content was sourced from clinicaltrials.gov

Similar Clinical Trials